30 April 2019
30(th) April 2019
("Physiomics") or ("the Company")
Conference attendance and presentation
Physiomics presents at the BioTrinity 2019 meeting in London
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it presented today at the BioTrinity 2019 annual conference in London. The presentation is available on the "resources" section of our website here https://www.physiomics.co.uk/wp-content/uploads/2019/04/Physiomics-Presentation-Biotrinity-2019.pdf.
The Company also took the opportunity to meet with a number of existing and potential new clients as well as to keep up to date with the latest in oncology drug development.
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (NOMAD)
+44 (0) 161 832 2174
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
This is an RNS Reach
Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour(TM) has been confirmed by over 70 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
(END) Dow Jones Newswires
April 30, 2019 09:00 ET (13:00 GMT)